Pharmacotherapy for uveitis: Current management and emerging therapy

Robert J. Barry; Quan Dong Nguyen; Richard Wlee; Philip Imurray; Alastair K. Denniston

doi:10.2147/OPTH.S47778

Pharmacotherapy for uveitis: Current management and emerging therapy

Robert J. Barry, Quan Dong Nguyen, Richard Wlee, Philip Imurray, Alastair K. Denniston

School of Medicine

Research output: Contribution to journal › Review article › peer-review

50 Scopus citations

Abstract

Uveitis, a group of conditions characterized by intraocular inflammation, is a major cause of sight loss in the working population. Most uveitis seen in Western countries is noninfectious and appears to be autoimmune or autoinflammatory in nature, requiring treatment with immunosuppressive and/or anti-inflammatory drugs. In this educational review, we outline the ideal characteristics of drugs for uveitis and review the data to support the use of current and emerging therapies in this context. It is crucial that we continue to develop new therapies for use in uveitis that aim to suppress disease activity, prevent accumulation of damage, and preserve visual function for patients with the minimum possible side effects.

Original language	English (US)
Pages (from-to)	1891-1911
Number of pages	21
Journal	Clinical Ophthalmology
Volume	8
DOIs	https://doi.org/10.2147/OPTH.S47778
State	Published - Sep 22 2014

Keywords

Clinical trials
Immunomodulatory therapeutic agents
Immunosuppression
Inflammation
Uvea

ASJC Scopus subject areas

Ophthalmology

Access to Document

10.2147/OPTH.S47778

Cite this

@article{d5ca298862f64d5bbe3f7ab0cd643599,

title = "Pharmacotherapy for uveitis: Current management and emerging therapy",

abstract = "Uveitis, a group of conditions characterized by intraocular inflammation, is a major cause of sight loss in the working population. Most uveitis seen in Western countries is noninfectious and appears to be autoimmune or autoinflammatory in nature, requiring treatment with immunosuppressive and/or anti-inflammatory drugs. In this educational review, we outline the ideal characteristics of drugs for uveitis and review the data to support the use of current and emerging therapies in this context. It is crucial that we continue to develop new therapies for use in uveitis that aim to suppress disease activity, prevent accumulation of damage, and preserve visual function for patients with the minimum possible side effects.",

keywords = "Clinical trials, Immunomodulatory therapeutic agents, Immunosuppression, Inflammation, Uvea",

author = "Barry, {Robert J.} and Nguyen, {Quan Dong} and Richard Wlee and Philip Imurray and Denniston, {Alastair K.}",

note = "Publisher Copyright: {\textcopyright} 2014 Barry et al.",

year = "2014",

month = sep,

day = "22",

doi = "10.2147/OPTH.S47778",

language = "English (US)",

volume = "8",

pages = "1891--1911",

journal = "Clinical Ophthalmology",

issn = "1177-5467",

publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Pharmacotherapy for uveitis

T2 - Current management and emerging therapy

AU - Barry, Robert J.

AU - Nguyen, Quan Dong

AU - Wlee, Richard

AU - Imurray, Philip

AU - Denniston, Alastair K.

PY - 2014/9/22

Y1 - 2014/9/22

N2 - Uveitis, a group of conditions characterized by intraocular inflammation, is a major cause of sight loss in the working population. Most uveitis seen in Western countries is noninfectious and appears to be autoimmune or autoinflammatory in nature, requiring treatment with immunosuppressive and/or anti-inflammatory drugs. In this educational review, we outline the ideal characteristics of drugs for uveitis and review the data to support the use of current and emerging therapies in this context. It is crucial that we continue to develop new therapies for use in uveitis that aim to suppress disease activity, prevent accumulation of damage, and preserve visual function for patients with the minimum possible side effects.

AB - Uveitis, a group of conditions characterized by intraocular inflammation, is a major cause of sight loss in the working population. Most uveitis seen in Western countries is noninfectious and appears to be autoimmune or autoinflammatory in nature, requiring treatment with immunosuppressive and/or anti-inflammatory drugs. In this educational review, we outline the ideal characteristics of drugs for uveitis and review the data to support the use of current and emerging therapies in this context. It is crucial that we continue to develop new therapies for use in uveitis that aim to suppress disease activity, prevent accumulation of damage, and preserve visual function for patients with the minimum possible side effects.

KW - Clinical trials

KW - Immunomodulatory therapeutic agents

KW - Immunosuppression

KW - Inflammation

KW - Uvea

UR - http://www.scopus.com/inward/record.url?scp=84907709770&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907709770&partnerID=8YFLogxK

U2 - 10.2147/OPTH.S47778

DO - 10.2147/OPTH.S47778

M3 - Review article

C2 - 25284976

AN - SCOPUS:84907709770

SN - 1177-5467

VL - 8

SP - 1891

EP - 1911

JO - Clinical Ophthalmology

JF - Clinical Ophthalmology

ER -

Pharmacotherapy for uveitis: Current management and emerging therapy

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this